{"_id": "650d0d33c9669d2e208ec2ca", "and": [{"$and": [{"prostate cancer histology": "adenocarcinoma of the prostate without small cell histology"}, {"prostate cancer progression on androgen deprivation therapy": true}, {"metastatic disease": true}, {"$or": [{"abiraterone acetate exposure": "abiraterone-na\u00efve"}, {"abiraterone acetate exposure": "received prior abiraterone acetate for the treatment of mHSPC or mCRPC, for a minimum of 4 weeks and not progressed while on treatment"}, {"abiraterone acetate exposure": "received prior abiraterone acetate for the treatment of mHSPC or mCRPC and progressed on treatment after a minimum of 8 weeks treatment (minimum 14 weeks for those with bone progression)"}]}, {"androgen deprivation": true}, {"bone resorptive therapy": true}, {"$and": [{"refrain from donating sperm": true}, {"$or": [{"be abstinent": true}, {"must agree to use male condom": true}]}]}, {"$or": [{"core or excisional biopsy from soft tissue": true}, {"bone biopsy sample": true}]}, {"ECOG performance status": {"$in": [0, 1]}}]}, {"$not": {"$or": [{"additional malignancy": true}, {"active autoimmune disease": true}, {"immunodeficiency or chronic systemic steroid therapy": true}, {"major surgery or gastrointestinal disorder": true}, {"active infection": true}, {"pneumonitis or interstitial lung disease": true}, {"active viral infections": true}, {"CNS metastases or carcinomatous meningitis": true}, {"hypersensitivity or seizure history": true}, {"loss of consciousness or blood pressure abnormalities": true}, {"bradycardia on ECG": true}, {"prostate cancer progression on ketoconazole": true}, {"prior treatment with certain agents": true}, {"prior therapy with radium or chemotherapy": true}, {"prior anti-cancer monoclonal antibody": true}, {"use of herbal products or recent vaccination": true}, {"participation in other studies or allogenic transplant": true}]}}], "nctId": "NCT03834493", "title": "A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)"}